A
Adam Brufsky
Researcher at University of Pittsburgh
Publications - 538
Citations - 33601
Adam Brufsky is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 74, co-authored 460 publications receiving 27570 citations. Previous affiliations of Adam Brufsky include MedStar Washington Hospital Center & Kaiser Permanente.
Papers
More filters
Journal ArticleDOI
Abstract P5-16-01: Assessment of health-related quality of life by clinical response from the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC)
Sibylle Loibl,Sara M. Tolaney,Kevin Punie,Mafalda Melo Oliveira,Hope S. Rugo,Aditya Bardia,Sara A. Hurvitz,Adam Brufsky,Kevin Kalinsky,Javier Cortes,Joyce O'Shaughnessy,Lisa A. Carey,Luca Gianni,Véronique Diéras,Mahdi Gharaibeh,Luciana Preger,Lee E. Moore,S Phan,Martine Piccart +18 more
TL;DR: Irrespective of their clinical response status, patients treated with SG showed more favorable LS mean changes than patients who received TPC in all EORTC QLQ-C30 domains, except for nausea/vomiting and diarrhea, and patients who achieved a tumor response to SG may benefit most in HRQoL.
Journal ArticleDOI
First-line treatment of metastatic breast cancer: current strategies and emerging systemic therapies
Journal ArticleDOI
Abstract PD17-01: Genomic analysis of circulating tumor DNA (ctDNA) from patients with HR+, HER2-mutant metastatic breast cancer (MBC) enrolled in SUMMIT: mechanisms of acquired resistance to neratinib + fulvestrant + trastuzumab (N+F+T)
Cynthia X. Ma,James R. Waisman,Adam Brufsky,Eddy S. Yang,Hans Wildiers,John Crown,Sarina Anne Piha-Paul,Jennifer Marie Suga,José A. García-Sáenz,Valentina Gambardella,Ángel L Guerrero,Salomon M. Stemmer,Ron Bose,Tonya Novara-Demgen,Daniel DiPrimeo,Lisa D. Eli,Komal Jhaveri +16 more
TL;DR: Ma et al. as mentioned in this paper investigated the mechanisms of acquired resistance to neratinibastrix + fulvestrant + trvimab (N+F+T) in patients with metastatic breast cancer.
Journal ArticleDOI
Clinical implications for patients with discordant oncotype and MammaPrint results.
Matei P. Socoteanu,Joyce O'Shaughnessy,Kent Hoskins,Adam Brufsky,C. Graham,Svetislava J. Vukelja,Jamal Misleh,Karen L. Tedesco,Rakhshanda Layeequr Rahman,June Taek Lee,Julian Berrocal,Kamal Sharma,Albert Begas,Jennifer A. Crozier,Ian Grady,Nina D'Abreo,Midas Kuilman,Holly M. Nguyen,Lisa Blumencranz,M. William Audeh +19 more
TL;DR: More than half of the patients in this cohort were at potential for undertreatment or overtreatment, and the risk to patients is far more significant in the event of undertreatment, as this may result in incurable metastatic recurrence.